The Global CRISPR Technology Market size is expected to be worth around USD 15.0 Billion by 2033 from USD 3.2 Billion in 2023, growing at a CAGR of 16.7% during the forecast period from 2024 to 2033.
In 2025, the CRISPR Technology Market is entering a new phase in industrial biomanufacturing and synthetic biology, as companies deploy genome-edited microbes for sustainable chemical, material, and biofuel production. Using CRISPR, microbial strains have been optimized to custom-produce high-value compounds such as bioplastics, specialty enzymes, and plant-based proteins. Pilot-scale bioreactors demonstrate efficient yields under industrial conditions, with reduced fermentation times and higher purity outputs. Companies are also creating modular CRISPR toolkits for rapid strain development in contract development and manufacturing (CDMO) pipelines.
As sustainability and demand for bio-based alternatives grow, CRISPR-engineered organisms are poised to reshape chemical manufacturing—offering greener, scalable production routes that align with circular economy goals.
Click here for more information:
https://market.us/report/crispr-technology-market/Key Market Segments
Product Type
Products
CRISPR Libraries
CRISPR Kits & Enzymes
Other Products
Services
Cell Line Engineering
gRNA Design & Vector Consultation
Screening Services
Other Services
Application
Biomedical
Industrial
Agricultural
Other Applications
End-User
Pharma & Biopharma Companies
Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations
Emerging Trends
CRISPR-edited microbes synthesizing biodegradable polymers and bio-based chemicals.
Modular genomic toolkits accelerating microbial strain engineering.
Pilot reactors demonstrating scalable, high-yield CRISPR strain performance.
CDMO partnerships offering custom genome engineering services for industrial clients.
Use Cases
A biotech startup uses CRISPR yeast strains to produce biodegradable packaging materials.
Industrial enzyme production is optimized via CRISPR-edited bacterial strains with elevated output.
A biofuel firm deploys CRISPR cyanobacteria engineered for high-efficiency carbon conversion.
CDMOs integrate CRISPR toolkits to deliver microbial prototypes to chemical manufacturers in weeks.
Locked
